115 related articles for article (PubMed ID: 27993680)
1. Co-crystal structures of PTK6: With Dasatinib at 2.24 Å, with novel imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 Å resolution.
Thakur MK; Birudukota S; Swaminathan S; Battula SK; Vadivelu S; Tyagi R; Gosu R
Biochem Biophys Res Commun; 2017 Jan; 482(4):1289-1295. PubMed ID: 27993680
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of the kinase domain of human protein tyrosine kinase 6 (PTK6) at 2.33 Å resolution.
Thakur MK; Kumar A; Birudukota S; Swaminathan S; Tyagi R; Gosu R
Biochem Biophys Res Commun; 2016 Sep; 478(2):637-42. PubMed ID: 27480927
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
Qiu L; Levine K; Gajiwala KS; Cronin CN; Nagata A; Johnson E; Kraus M; Tatlock J; Kania R; Foley T; Sun S
PLoS One; 2018; 13(6):e0198374. PubMed ID: 29879184
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
Zeng H; Belanger DB; Curran PJ; Shipps GW; Miao H; Bracken JB; Arshad Siddiqui M; Malkowski M; Wang Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5870-5. PubMed ID: 21855335
[TBL] [Abstract][Full Text] [Related]
5. Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK.
Brauer PM; Tyner AL
Biochim Biophys Acta; 2010 Aug; 1806(1):66-73. PubMed ID: 20193745
[TBL] [Abstract][Full Text] [Related]
6. Exon-intron structure of the human PTK6 gene demonstrates that PTK6 constitutes a distinct family of non-receptor tyrosine kinase.
Lee H; Kim M; Lee KH; Kang KN; Lee ST
Mol Cells; 1998 Aug; 8(4):401-7. PubMed ID: 9749526
[TBL] [Abstract][Full Text] [Related]
7. Solution structure and backbone dynamics of the non-receptor protein-tyrosine kinase-6 Src homology 2 domain.
Hong E; Shin J; Kim HI; Lee ST; Lee W
J Biol Chem; 2004 Jul; 279(28):29700-8. PubMed ID: 15056653
[TBL] [Abstract][Full Text] [Related]
8. PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors.
Peng M; Emmadi R; Wang Z; Wiley EL; Gann PH; Khan SA; Banerji N; McDonald W; Asztalos S; Pham TN; Tonetti DA; Tyner AL
Oncotarget; 2014 Aug; 5(15):6038-48. PubMed ID: 25153721
[TBL] [Abstract][Full Text] [Related]
9. Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.
Tsui T; Miller WT
Biochemistry; 2015 May; 54(20):3173-82. PubMed ID: 25940761
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 rescues PTK6 from proteasomal degradation in breast cancer cells.
Kang SA; Cho HS; Yoon JB; Chung IK; Lee ST
Biochem J; 2012 Oct; 447(2):313-20. PubMed ID: 22849407
[TBL] [Abstract][Full Text] [Related]
11. Molecular dissection of the interaction between the SH3 domain and the SH2-Kinase Linker region in PTK6.
Kim HIe; Jung J; Lee ES; Kim YC; Lee W; Lee ST
Biochem Biophys Res Commun; 2007 Nov; 362(4):829-34. PubMed ID: 17822667
[TBL] [Abstract][Full Text] [Related]
12. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of the auto-inhibition mechanism of nonreceptor tyrosine kinase PTK6.
Ko S; Ahn KE; Lee YM; Ahn HC; Lee W
Biochem Biophys Res Commun; 2009 Jun; 384(2):236-42. PubMed ID: 19401189
[TBL] [Abstract][Full Text] [Related]
15. Discovery of (E)-5-(benzylideneamino)-1H-benzo[d]imidazol-2(3H)-one derivatives as inhibitors for PTK6.
Shim HJ; Yang HR; Kim HI; Kang SA; No KT; Jung YH; Lee ST
Bioorg Med Chem Lett; 2014 Oct; 24(19):4659-4663. PubMed ID: 25205190
[TBL] [Abstract][Full Text] [Related]
16. Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.
Ludyga N; Anastasov N; Gonzalez-Vasconcellos I; Ram M; Höfler H; Aubele M
Mol Biosyst; 2011 May; 7(5):1603-12. PubMed ID: 21380407
[TBL] [Abstract][Full Text] [Related]
17. HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.
Ai M; Qiu S; Lu Y; Fan Z
Cell Signal; 2013 Sep; 25(9):1754-61. PubMed ID: 23707532
[TBL] [Abstract][Full Text] [Related]
18. PTK6 inhibits down-regulation of EGF receptor through phosphorylation of ARAP1.
Kang SA; Lee ES; Yoon HY; Randazzo PA; Lee ST
J Biol Chem; 2010 Aug; 285(34):26013-21. PubMed ID: 20554524
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper.
Wang Z; Liu J; Sudom A; Ayres M; Li S; Wesche H; Powers JP; Walker NP
Structure; 2006 Dec; 14(12):1835-44. PubMed ID: 17161373
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib Inhibits Active PTK6 in
Wozniak DJ; Hitchinson B; Gilic MB; Bie W; Gaponenko V; Tyner AL
Mol Cancer Ther; 2019 May; 18(5):937-946. PubMed ID: 30926642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
